• ARCA EGFP mRNA for Transfection Workflows

  2026-09-11

  ARCA EGFP mRNA provides a direct fluorescence readout for comparing delivery, translation, and cell recovery in mammalian systems. Use it as an mRNA transfection control for lipid reagents, lipid nanoparticles, or localized electroporation while pairing fluorescence with orthogonal viability or impedance measurements.

• Chenodeoxycholic Acid for FXR-KLF11 Studies

  2026-09-11

  Use Chenodeoxycholic Acid as a practical FXR perturbation for connecting bile acid metabolism with KLF11, JAK2/STAT3, inflammation, and tubular-cell injury. This workflow emphasizes solvent control, dose-finding, genetic validation, and transcriptional readouts so CDCA results remain interpretable across renal and metabolic research.

• Phytol Workflows for RXR Assay Optimization

  2026-09-10

  Build more interpretable RXR experiments with a solvent-aware, isomer-conscious workflow for Phytol and trans-Phytol. A soft-matter-inspired design strategy adds matrix controls, kinetic checkpoints, and orthogonal readouts without confusing polymer self-assembly evidence with receptor biology.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-09-10

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with stromal cell subpopulations from the same tumor. The model revealed that stromal composition changes gene expression and drug sensitivity, providing a more physiologically relevant platform for tumor–stroma studies and personalized treatment testing.

• RAB31 and ESCRT-Independent Exosome Biogenesis

  2026-09-09

  The reference study identifies RAB31 as a regulator that both drives intraluminal vesicle formation and prevents multivesicular endosome degradation. Its findings connect EGFR phosphorylation, flotillin lipid-raft domains, and TBC1D2B-mediated RAB7 inactivation into an ESCRT-independent exosome pathway with important implications for membrane trafficking research.

• ML216 BLM Helicase Inhibitor: Assay Guide

  2026-09-09

  ML216 provides a practical way to interrogate BLM-dependent DNA repair, sister chromatid exchange, and genotype-selective tumor cell responses. This guide translates its biochemical selectivity into cell-based workflows while clarifying how findings from MSI colorectal cancer studies should—and should not—be applied to BLM research.

• CFDA SE Cell Tracer Kit: Practical Workflow

  2026-09-09

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing, cell proliferation studies, and related in vitro or in vivo tracking workflows. It is appropriate when covalent, multi-day marking is needed, but not when reversible labeling, rapid dye clearance, or real-time physiological monitoring is required.

• Topotecan: From Topo I Lesions to Assay Design

  2026-09-08

  Topotecan, also known as SKF104864, is examined here through a pharmacology-to-assay framework that connects lactone chemistry, replication-fork damage, exposure scheduling, and translational interpretation. The article provides a distinct strategy for using this topoisomerase I inhibitor in cancer research, including glioma and pediatric tumor models.

• Concanavalin A and Conserved Coronavirus N-Glycans

  2026-09-07

  Guo and colleagues identify conserved high-mannose N-glycosylation sites near the coronavirus spike S2′ cleavage region as a broad-spectrum antiviral vulnerability. Using fusion, pseudovirus, authentic-virus, biochemical, and animal models, the study shows that concanavalin A blocks spike activation and reduces hCoV-NL63 disease in vivo, while also defining important limits for translation.

• REV1–DHX36 Coordinates G-Quadruplex Tolerance

  2026-09-07

  Ketkar and colleagues identify a direct REV1–DHX36 interaction that couples G-quadruplex unwinding with suppression of single-stranded DNA gaps during replication. The study shows that REV1 loss redirects fork progression toward PrimPol-dependent synthesis, elevates DNA damage signaling, and increases sensitivity to G-quadruplex stabilization, providing a mechanistic framework for genome-integrity research.

• FK866 (APO866): NAD Metabolism as an Assay Lens

  2026-09-05

  Explore how FK866 (APO866) converts NAMPT inhibition into interpretable metabolic, mitochondrial, and cell-death phenotypes. This article connects AML research with PARP-inhibitor resistance biology while providing a practical framework for designing rigorous, multi-endpoint assays.

• FPS-ZM1: A Causal RAGE Assay Framework

  2026-09-04

  FPS-ZM1 is a selective RAGE inhibitor for dissecting amyloid beta signaling, neuroinflammation, and RAGE/POMC biology. This assay-focused guide explains how to separate ligand transport, neuronal stress, and metabolic signaling without overstating preclinical evidence.

• Streptavidin-FITC for Biotin Detection Workflows

  2026-09-04

  Streptavidin-FITC converts biotinylated antibodies, nucleic acids, and nanoparticles into measurable fluorescent signals for imaging and flow cytometry. This practical guide combines assay setup, LNP-delivery applications, protocol starting points, and troubleshooting for more reproducible biotin detection.

• AO/PI Double Staining Kit for Glioma Organoids

  2026-09-03

  Learn how the AO/PI Double Staining Kit can support cell viability assay design in patient-derived glioma organoids. This guide connects Acridine Orange Propidium Iodide staining with microenvironment preservation, spatial interpretation, and better drug-screening decisions.

• circRHOBTB3 and Metastatic Prostate Cancer

  2026-09-03

  A 2025 Cancer Letters study identifies circRHOBTB3 as a suppressive circular RNA that limits prostate cancer proliferation and metastasis by retaining NONO in the cytoplasm and reducing MAOA transcription. The work also connects circRNA function with biogenesis by showing that SRSF9 binding to Alu elements inhibits circRHOBTB3 circularization, providing a mechanistic framework for biomarker and therapeutic research.

8543 records 1/570 page Next 12345 下5页 Last page